London, United Kingdom

Adina Michael-Titus

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: University of London. Active years: 2013.


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Adina Michael-Titus: Innovator in Alzheimer's Research

Introduction

Adina Michael-Titus is a prominent inventor based in London, GB. She has made significant contributions to the field of biomedical research, particularly in the area of Alzheimer's disease. Her innovative work focuses on developing novel compounds that can potentially improve the treatment of this debilitating condition.

Latest Patents

Adina holds a patent for "Substituted phosphonates and their use in decreasing amyloid aggregates." This invention relates to both novel and known substituted phosphonates that are designed to ameliorate amyloid aggregates, which are associated with Alzheimer's disease. The patent highlights her commitment to advancing medical science and finding solutions for complex health issues.

Career Highlights

Throughout her career, Adina has worked with esteemed institutions such as the University of London and Queen Mary & Westfield College. Her experience in these academic environments has allowed her to collaborate with leading researchers and contribute to groundbreaking studies in her field.

Collaborations

Adina has collaborated with notable colleagues, including Lesley Robson and Alice Caroline Sullivan. These partnerships have enriched her research and expanded the impact of her work in the scientific community.

Conclusion

Adina Michael-Titus is a dedicated inventor whose work in developing treatments for Alzheimer's disease showcases her innovative spirit and commitment to improving human health. Her contributions to the field are invaluable and continue to inspire future research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…